“We are pleased to report new pharmacokinetic and pharmacodynamic data from our MET409 Phase 1b proof-of-concept clinical trial in patients with NASH, a prevalent and potentially life ...

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH ...